Loading...
Market
Will Zepbound receive FDA approval for expanded obesity treatment use by end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA official announcements and press releases
Story
Eli Lilly's Zepbound Achieves 20.2% Weight Loss, Surpassing Wegovy in Head-to-Head Trial
Dec 4, 2024, 02:10 PM
Eli Lilly announced that its obesity drug Zepbound (tirzepatide) has shown superior results to Novo Nordisk's Wegovy (semaglutide) in the first large, head-to-head trial of the two weight-loss medications. The SURMOUNT-5 Phase 3B trial included 751 adults with obesity or overweight, without type 2 diabetes, each having at least one obesity-related condition such as hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. Over 72 weeks, patients taking Zepbound lost an average of 20.2% of their body weight (approximately 50.3 lbs or 22.8 kg), compared to a 13.7% weight loss (approximately 33.1 lbs or 15.0 kg) for those on Wegovy. These results indicate that Zepbound provided a 47% greater relative weight loss compared to Wegovy, highlighting its potential as a more effective treatment for obesity.
View original story
Similar markets
No • 50%
Yes • 50%
10% to 20% • 25%
More than 30% • 25%
20% to 30% • 25%
Less than 10% • 25%
Medicines and Healthcare products Regulatory Agency (MHRA) • 25%
Therapeutic Goods Administration (TGA) • 25%
Other • 25%
European Medicines Agency (EMA) • 25%
Yes • 50%
No • 50%
5 to 10 • 25%
Less than 5 • 25%
More than 15 • 25%
11 to 15 • 25%